ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,161.50
-0.15%
S&P 500
5,308.15
0.00%
Dow Jones
39,908.00
0.00%
US Dollar vs Yen
154.8245
0.35%
Brent Oil
82.96
0.37%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) ニュース

ARGX argenx SE

376.96
0.00 (0.00%)
プレマーケット
最終更新日： 21:30:50
15分遅延
名称 銘柄コード 市場 種別
argenx SE ARGX NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
Upgrade Icon
0.00 0.00% 376.96 21:30:50
始値 安値 高値 終値 前日終値
376.96
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0920:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/5/0914:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
2024/5/0819:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/5/0806:30GLOBEargenx announces results of Annual General Meeting of..
2024/5/0714:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
2024/5/0214:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
2024/4/1614:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
2024/3/2715:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
2024/3/2705:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
2024/3/2615:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
2024/3/0820:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/3/0806:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
2024/3/0106:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2915:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
2024/2/2615:00GLOBEargenx to Present at Upcoming Investor Conferences
2024/2/2215:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
2024/2/2020:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/2/2015:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
2024/1/1820:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/1815:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
2024/1/0820:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0815:00GLOBEargenx Highlights 2024 Strategic Priorities
2024/1/0215:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
2023/12/2102:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
2023/12/2020:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/2015:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
2023/11/2901:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
2023/11/2821:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
2023/11/2820:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/2815:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
2023/11/1720:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/1621:40GLOBEargenx Announces European Commission Approval of..
2023/11/0205:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/0115:00GLOBEargenx to Present at Upcoming Investor Conferences
2023/10/3122:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/3115:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
2023/10/2414:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
2023/9/2805:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
2023/9/2121:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/2114:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
2023/9/1514:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
2023/8/3014:00GLOBEargenx to Present at Upcoming Investor Conferences
2023/7/2719:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2714:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
2023/7/2505:30GLOBEargenx announces closing of global offering
2023/7/2105:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2023/7/2014:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
2023/7/2006:58GLOBEargenx announces full exercise of underwriters’ option to..
2023/7/1910:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
2023/7/1805:58DJNArgenx Launches $750 Million Global Offering

最近閲覧した銘柄

NASDAQ
ARGX
argenx
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有